Doximity Förvaltning
Förvaltning kriterier kontrolleras 1/4
Doximity VD är Jeff Tangney, utsedd i Apr 2010, har en mandatperiod på 16.08 år. totala årliga ersättningen är $ 17.23M, bestående av 3.5% lön 96.5% bonusar, inklusive företagsaktier och optioner. äger direkt 27.24% av företagets aktier, värda $ 989.30M. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 0.8 år respektive 10.7 år.
Viktig information
Jeff Tangney
Verkställande direktör
US$17.2m
Total ersättning
| VD-lön i procent | 3.48% |
| Anställning som VD | 16.1yrs |
| Ägande av VD | 27.2% |
| Ledningens genomsnittliga anställningstid | less than a year |
| Styrelsens genomsnittliga mandatperiod | 10.7yrs |
Senaste uppdateringar av ledningen
Recent updates
Seeking Alpha • May 15
Doximity Earnings: Strong AI Signals, But Monetization Still Pending
Summary Doximity, Inc. delivered mixed FY26 results, with solid revenue growth but margin compression and a cautious near-term outlook. AI-driven engagement is accelerating, with rapid adoption of clinical tools and strong enterprise traction, but monetisation lags due to regulatory and operational friction. FY27 is positioned as a transition year, with guidance for just 4% revenue growth and EBITDA margin compression as AI investments ramp. DOCS' valuation now reflects a more mature SaaS profile, trading below historical multiples, as the market prices in execution and growth transition risks. Read the full article on Seeking Alpha
Uppdatering av berättelse • May 09
DOCS: AI Suite And Platform Stickiness Will Support Higher Future Earnings Power
Analysts trimmed their Doximity fair value estimate to $55.00 from $56.00, reflecting reduced revenue growth assumptions, partly offset by expectations for slightly higher profit margins and a marginally richer future P/E multiple following a series of recent price target cuts and mixed rating changes across the Street. Analyst Commentary Recent Street research on Doximity has been mixed, with a cluster of price target cuts and rating changes alongside a handful of more constructive views.
Uppdatering av berättelse • Apr 21
DOCS: Healthcare Moat And AI Tools Will Support Future Engagement
The updated analyst price target for Doximity reflects a modest fair value reduction of about $1.77 per share, as analysts factor in weaker revenue growth visibility highlighted in several recent downgrades and target cuts, while also noting resilient margins and interest in the company’s AI tool suite. Analyst Commentary Recent research on Doximity presents a mix of optimism around the platform and its AI tools, alongside concern about the visibility and durability of revenue growth.Uppdatering av berättelse • Apr 07
DOCS: Rebased Sentiment And Healthcare Moat Will Support Future Engagement
The updated analyst price target for Doximity moves from about $63.57 to roughly $39.55. This reflects lower modeled revenue growth, profit margins and future P/E multiples, even as several firms highlight the platform's network effects, AI tools and healthcare marketing traction as key long term strengths.
Uppdatering av berättelse • Mar 24
DOCS: AI Tools And Buybacks Will Shape A Cautious Balanced Outlook
Analysts held the Doximity fair value estimate steady at $25.00, while modestly adjusting assumptions after mixed but generally constructive price target moves that highlight interest in the platform's AI tools, network effects, and healthcare marketing exposure. Analyst Commentary Recent Street research on Doximity reflects a split view, with some firms highlighting the medical AI tool suite, network effects and healthcare marketing exposure, while others reset expectations through lower price targets and more neutral ratings.Uppdatering av berättelse • Mar 09
DOCS: AI Tools And Share Buybacks Will Drive Shares Higher
Doximity's updated fair value estimate has decreased to $56.00 from $68.90, reflecting analysts' reduced price targets from several firms, alongside ongoing support for the company's AI tools and healthcare marketing position. Analyst Commentary Street research on Doximity has been mixed, but there is a clear cluster of bullish analysts who see support for the story in healthcare marketing, AI tools and the company’s position with U.S. physicians.Uppdatering av berättelse • Feb 23
DOCS: AI Suite And Share Buybacks Will Shape A More Balanced Outlook
The analyst fair value estimate for Doximity has been revised to $25 from $50, reflecting a wave of reduced price targets across several firms, even as some analysts highlight potential from the company’s AI tools and broader healthcare marketing ecosystem. Analyst Commentary Recent research on Doximity shows a split tape, with some firms cutting price targets sharply while others highlight potential upside tied to the company’s tools and healthcare marketing position.Uppdatering av berättelse • Feb 09
DOCS: Pharma Ad Shift And Share Buybacks Will Drive Shares Higher
Analysts have reduced their Doximity fair value estimate from about US$83 to roughly US$69. This reflects updated expectations for more moderate revenue growth, slightly lower profit margins and a reduced future P/E multiple, even as several firms highlight the company’s strong position in digital healthcare marketing and its expanding product tools.Analysartikel • Feb 06
Doximity, Inc.'s (NYSE:DOCS) Popularity With Investors Under Threat As Stock Sinks 27%
To the annoyance of some shareholders, Doximity, Inc. ( NYSE:DOCS ) shares are down a considerable 27% in the last...Uppdatering av berättelse • Jan 26
DOCS: Rebased Sentiment And Strong Moat Will Support Future Engagement
Narrative Update on Doximity The analyst fair value estimate for Doximity has been adjusted from US$65.25 to about US$63.57 as analysts factor in lower target prices, along with continued confidence in the company's moat, market share gains, and higher reported ROI compared with other digital healthcare marketing platforms. Analyst Commentary Recent research on Doximity highlights a mix of optimism and caution as analysts update ratings and price targets while reassessing growth, execution, and risk pricing.Uppdatering av berättelse • Jan 11
DOCS: Rebased Sentiment And Budget Shifts Will Support Stronger Engagement
Our updated analyst price target framework for Doximity moves fair value from US$71.11 to US$65.25 as analysts recalibrate growth, discount rate and forward P/E assumptions, while still pointing to strengthening platform engagement and expanding tools such as OpenEvidence, as well as what several describe as a defensible competitive position in healthcare professional marketing. Analyst Commentary Recent Street research on Doximity reflects a mix of optimism around the core franchise and its tools such as OpenEvidence, alongside a more cautious reset on valuation and competitive risk.Uppdatering av berättelse • Dec 26
DOCS: Budget Flush And Pharma Ad Shift Will Drive Shares Higher
We modestly raised our Doximity price target to $83.00 per share from $62.00, as analysts highlight improving long term growth visibility, accelerating video driven revenue momentum, and an increasingly compelling risk reward profile following the recent pullback, despite ongoing debate around pharma digital ad trends. Analyst Commentary Bullish analysts are increasingly highlighting Doximity as a high conviction idea following the post earnings selloff, pointing to a more attractive entry point relative to its vertical software peers.Uppdatering av berättelse • Dec 12
DOCS: Budget Flush And Ad Shift Will Drive Shares Higher
Analysts have lifted their Doximity fair value estimate to $83.00 from $78.58, reflecting stronger expected revenue growth and improving long term growth visibility, which they believe more than offset lower margin assumptions and a higher required return. Analyst Commentary Bullish analysts highlight that the recent pullback in Doximity shares has created a compelling entry point, with the stock now trading at what they view as an unjustified discount to the broader vertical software peer group.Analysartikel • Nov 14
Doximity, Inc. (NYSE:DOCS) May Have Run Too Fast Too Soon With Recent 26% Price Plummet
The Doximity, Inc. ( NYSE:DOCS ) share price has fared very poorly over the last month, falling by a substantial 26...Uppdatering av berättelse • Nov 01
DOCS: Pharma Advertising Shift And AI Expansion Will Drive Measured Opportunity And Risks
Analysts have modestly increased their price target for Doximity, raising the estimate from $70.72 to $71.11 per share. They cite stronger revenue momentum, which is supported by recent upgrades and expectations for higher provider-driven growth.Uppdatering av berättelse • Oct 18
AI Integration And Telehealth Expansion Will Transform The Healthcare Industry
Analysts have raised their price target for Doximity from $69.50 to $70.72. They cited slightly improved profit margin forecasts and increased confidence in the company’s platform engagement as advertising trends evolve.Uppdatering av berättelse • Oct 04
AI Integration And Telehealth Expansion Will Transform The Healthcare Industry
Doximity's analyst price target has increased from $68.67 to $69.50 per share. This change reflects analysts' positive view on strong business momentum, promising AI initiatives, and a conservative outlook for fiscal 2026 revenue growth.Uppdatering av berättelse • Sep 13
AI Integration And Telehealth Expansion Will Transform The Healthcare Industry
Doximity’s price target was raised modestly to $68.67 as analysts pointed to robust Q1 results, AI-driven strategy enhancements, and conservative guidance as drivers of sustained business momentum. Analyst Commentary Bullish analysts cite strong Q1 results and upwardly revised guidance as evidence of solid business momentum.Analysartikel • Sep 02
At US$67.94, Is Doximity, Inc. (NYSE:DOCS) Worth Looking At Closely?
Doximity, Inc. ( NYSE:DOCS ) saw a significant share price rise of 32% in the past couple of months on the NYSE...Analysartikel • Aug 15
We Think Doximity's (NYSE:DOCS) Profit Is Only A Baseline For What They Can Achieve
NYSE:DOCS 1 Year Share Price vs Fair Value Explore Doximity's Fair Values from the Community and select yours When...Uppdatering av berättelse • Aug 10
AI Integration And Telehealth Expansion Will Transform The Healthcare Industry
Doximity’s fair value outlook has improved as reflected by a higher consensus price target, despite a notable contraction in net profit margin and a rising future P/E multiple signaling higher growth expectations. What's in the News Doximity provided revenue guidance for FY26 of $628–636 million and Q2 FY26 of $157–158 million.Analysartikel • Jul 08
Getting In Cheap On Doximity, Inc. (NYSE:DOCS) Is Unlikely
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") below 18x, you may...Analysartikel • Jun 23
With EPS Growth And More, Doximity (NYSE:DOCS) Makes An Interesting Case
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Analysartikel • May 17
At US$52.56, Is Doximity, Inc. (NYSE:DOCS) Worth Looking At Closely?
Let's talk about the popular Doximity, Inc. ( NYSE:DOCS ). The company's shares saw significant share price movement...Analysartikel • May 01
Calculating The Intrinsic Value Of Doximity, Inc. (NYSE:DOCS)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Doximity fair value estimate is US$54.31 With US$56.88 share...Analysartikel • Apr 04
Shareholders Are Optimistic That Doximity (NYSE:DOCS) Will Multiply In Value
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Analysartikel • Feb 23
What Doximity, Inc.'s (NYSE:DOCS) 28% Share Price Gain Is Not Telling You
Despite an already strong run, Doximity, Inc. ( NYSE:DOCS ) shares have been powering on, with a gain of 28% in the...Seeking Alpha • Feb 10
Doximity Q3 Earnings: Outpacing Even Management's Expectations
Summary I previously rated Doximity, Inc. a buy due to strong Q2 earnings, favorable DCF analysis, and its strategic position in the healthcare industry. Q3 earnings showed continued strength, with DOCS stock up 56% compared to the S&P 500's 2% return since my last analysis. Updated DCF valuation, incorporating management guidance and industry trends, suggests a new price target of $90, indicating 14% upside from today. Doximity's product-market fit remains nearly perfect, with robust revenue growth and efficient cost scaling, supporting a continued buy rating. Read the full article on Seeking AlphaAnalysartikel • Jan 24
When Should You Buy Doximity, Inc. (NYSE:DOCS)?
Today we're going to take a look at the well-established Doximity, Inc. ( NYSE:DOCS ). The company's stock led the NYSE...Seeking Alpha • Jan 13
Doximity: Upgraded To Buy Amid Promising Growth And Strong Execution
Summary Upgraded Doximity to a buy rating due to recent share price pullback, stronger engagement metrics, and deeper client relationships, creating a compelling entry point. DOCS reported 20% y/y revenue growth in 2Q25, surpassing management's guidance, with increased user adoption and higher revenue per user driving performance. The adoption of AI-driven tools and expanded Client Portal access are enhancing the Company's value proposition, leading to higher engagement and better-targeted advertising for pharma clients. Read the full article on Seeking AlphaAnalysartikel • Jan 06
Here's Why We Think Doximity (NYSE:DOCS) Is Well Worth Watching
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Seeking Alpha • Dec 06
Doximity: Strong Fundamentals And Growth Potential Makes It Attractive
Summary Doximity's dominance in digital healthcare is evident with over 80% of U.S. doctors using the platform, driving strong network effects and competitive positioning. The company boasts impressive financials, with earnings surpassing expectations, strong cash reserves, and high margins, indicating robust scalability and efficiency. New AI-powered features and product launches enhance clinical workflows, while leadership's proven track record supports continued market expansion and service broadening. Despite premium valuation and regulatory challenges, Doximity's market leadership, financial health, and growth potential make it a compelling long-term investment in healthcare technology. Read the full article on Seeking AlphaAnalysartikel • Dec 01
Doximity (NYSE:DOCS) Knows How To Allocate Capital
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...Analysartikel • Nov 13
Earnings Not Telling The Story For Doximity, Inc. (NYSE:DOCS) After Shares Rise 34%
Despite an already strong run, Doximity, Inc. ( NYSE:DOCS ) shares have been powering on, with a gain of 34% in the...Analys av ersättningar till VD
| Datum | Total ersättning | Lön | Företagets resultat |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$196m |
| Dec 31 2025 | n/a | n/a | US$239m |
| Sep 30 2025 | n/a | n/a | US$253m |
| Jun 30 2025 | n/a | n/a | US$235m |
| Mar 31 2025 | US$17m | US$600k | US$223m |
| Dec 31 2024 | n/a | n/a | US$201m |
| Sep 30 2024 | n/a | n/a | US$174m |
| Jun 30 2024 | n/a | n/a | US$161m |
| Mar 31 2024 | US$299k | US$295k | US$148m |
| Dec 31 2023 | n/a | n/a | US$138m |
| Sep 30 2023 | n/a | n/a | US$123m |
| Jun 30 2023 | n/a | n/a | US$119m |
| Mar 31 2023 | US$244k | US$240k | US$113m |
| Dec 31 2022 | n/a | n/a | US$119m |
| Sep 30 2022 | n/a | n/a | US$141m |
| Jun 30 2022 | n/a | n/a | US$148m |
| Mar 31 2022 | US$243k | US$240k | US$133m |
| Dec 31 2021 | n/a | n/a | US$107m |
| Sep 30 2021 | n/a | n/a | US$57m |
| Jun 30 2021 | n/a | n/a | US$30m |
| Mar 31 2021 | US$21m | US$240k | US$22m |
Ersättning vs marknad: Jeff s total kompensation ($USD 17.23M ) är över genomsnittet för företag av liknande storlek på US marknaden ($USD 7.11M ).
Ersättning vs inkomst: Ersättningen för Jeff har ökat med mer än 20 % medan företagets intäkter har minskat med mer än 20 % det senaste året.
VD OCH KONCERNCHEF
Jeff Tangney (52 yo)
16.1yrs
Anställning
US$17,234,989
Kompensation
Mr. Jeffrey A. Tangney, also known as Jeff, Co-Founded Doximity, Inc. in 2010 and has been its Chief Executive Officer and Director since April 2010 and serves as its Chairperson. Mr. Tangney also serves a...
Ledningsgrupp
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| Co-Founder | 16.1yrs | US$17.23m | 27.24% $ 989.3m | |
| Advisor & Co-Founder | no data | US$1.52m | 0.25% $ 9.1m | |
| President | no data | inga uppgifter | inga uppgifter | |
| Co-founder and SVP People & Ops | no data | inga uppgifter | inga uppgifter | |
| Chief Financial Officer | no data | inga uppgifter | inga uppgifter | |
| Chief Accounting Officer and Interim Principal Financial & Accounting Officer | no data | inga uppgifter | 0.035% $ 1.3m | |
| Chief Technology Officer | no data | inga uppgifter | inga uppgifter | |
| Head of Investor Relations | no data | inga uppgifter | inga uppgifter | |
| General Counsel | less than a year | inga uppgifter | inga uppgifter | |
| Senior Vice President of Engineering | no data | inga uppgifter | inga uppgifter | |
| Senior Vice President of Product | no data | inga uppgifter | inga uppgifter | |
| Senior VP & GM Commercial Products | 3yrs | inga uppgifter | inga uppgifter |
0.8yrs
Genomsnittlig anställningstid
48.5yo
Genomsnittlig ålder
Erfaren ledning: DOCS s ledningsgrupp anses inte vara erfaren ( 0.8 års genomsnittlig anställningstid), vilket föreslår ett nytt team.
Styrelseledamöter
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| Co-Founder | 16.1yrs | US$17.23m | 27.24% $ 989.3m | |
| Member of Medical Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Independent Director | 5.7yrs | US$287.10k | inga uppgifter | |
| Independent Director | 15.2yrs | US$291.35k | 0.14% $ 5.0m | |
| Member of Medical Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Member of Medical Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Member of Medical Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Member of Medical Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Member of Medical Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Member of Medical Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Member of Medical Advisory Board | no data | inga uppgifter | inga uppgifter | |
| Independent Director | 6.2yrs | US$282.97k | 0.0091% $ 330.1k |
10.7yrs
Genomsnittlig anställningstid
52.5yo
Genomsnittlig ålder
Erfaren styrelse: DOCS s styrelse är rutinerade och erfaren ( 10.7 års genomsnittlig mandatperiod).
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/21 21:36 |
| Aktiekurs vid dagens slut | 2026/05/21 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2026/03/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Doximity, Inc. bevakas av 28 analytiker. 22 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Vikram Kesavabhotla | Baird |
| Glen Santangelo | Barclays |
| Nisala Weerasuriya | Berenberg |